- Market Intelligence
- News Data Feeds API
- Executive Briefings
- About Us
- Contact Us
- Case Studies
- Data Sheets
NEW YORK (GenomeWeb) – The Association of Community Cancer Centers (ACCC), a cancer care provider advocacy group, announced today that Pfizer will provide $1.5 million in grant funding to support initiatives integrating BRCA testing into patient care plans.
Celgene has added a $65 million upfront portion of oncology discovery work with Evotec, 18 months after the two companies allied on neurodegeneration work. As is typically the case with Celgene $CELG and Evotec, there aren’t an awful lot of details to work with.
Pfizer Reports Positive Topline Results in Children’s Epilepsy Drug Trial Pfizer Reports Positive Topline Results in Children’s Epilepsy Drug Trial Evan Dion | May 21, 2018 | Pfizer (PFE) shares were barely higher pre-market Thursday after the drugmaker reported positive top-line results from a phase 3 study of the drug Lyrica as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.
May 21 (Reuters) - Evotec Ag: * DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP * UNDER TERMS OF AGREEMENT, EVOTEC WILL RECEIVE AN UPFRONT PAYMENT OF $65 MILLION * CELGENE RECEIVES EXCLUSIVE OPT-IN
Pharmaceutical company Novartis, in collaboration with the National Blood Transfusion Service and the Lagos State Blood Transfusion Service, recently organized a blood donation drive where Novartis employees voluntarily donated blood to save the lives of patients.
NYSE- and LSE-listed AstraZeneca PLC (AZN) announced that it has secured approval from the U.S. Food and Drug Administration (FDA) for Lokelma (sodium zirconium cyclosilicate), earlier known as ZS-9, for the treatment of adults with hyperkalemia.
Traders may be keeping a close eye on ATR indicators. The current 14-day ATR for Pfizer Inc (PFE) is currently sitting at 0.51. The ATR measures the volatility of a stock on a day-to-day basis. The average true range is typically based on 14 periods and may be calculated daily, weekly, monthly, or intraday.
Takeda, already heavily in debt, is taking on more loans to acquire Irish drugmaker Shire. © Reuters TOKYO -- Takeda Pharmaceutical will divest its majority stake in a Chinese joint venture, seeking to secure its financial footing as it prepares to acquire Irish drugmaker Shire.
AstraZeneca announced Monday the US Food and Drug Administration had approved its treatment for hyperkalaemia, a serious condition associated with elevated levels of potassium in the blood. The US Food and Drug Administration's approval of Lokelma, an oral potassium-removing agent, was supported by data from three double-blind, placebo-controlled trials and two open-label trials showing the drug helped to normalise potassium levels.
EMBOTRAP II Revascularization Device Captures and Removes Life-threatening Blood Clots, Rapidly Restores Blood Flow Irvine, Calif. – MAY 21 – CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S.
Can Minnesota become a healthcare innovation hub? Minnesota has the institutions and the talent to transform healthcare in the U.S. The question is whether the money will follow. RxFunction makes wearable devices called “Walkasins” that help people with chronic health conditions prevent falls that can lead to serious injury.
(MENAFN Editorial) WINDHOEK, Namibia, May 21, 2018/APO Group/ -- Merck Foundation launches their ‘Merck More Than a Mother' to build fertility care capacity and break the stigma around infertile women. Merck Foundation appoints the Chairperson of National Council of Namibia, as an Ambassador of Merck More than a Mother in the country.
A Deadline is coming up on May 28, 2018 in the lawsuit for investors in Celgene Corporation (NASDAQ: CELG) and NASDAQ: CELG stockholders should contact the Shareholders Foundation. This press release was orginally distributed by SBWire San Diego, CA -- (SBWIRE) -- 05/21/2018 -- A deadline is coming up on May 28, 2018 in the lawsuit filed for certain investors in NASDAQ: CELG shares over alleged securities laws violations by Celgene Corporation.
As per the agreement, Emulate will embed its technology in the laboratories of AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit. AstraZeneca began collaborating on the technology in 2013, before Emulate was spun out of the Wyss Institute at Harvard University in July 2014.
The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration (FDA) finally gave its approval for the treatment that was the primary focus of the 2015 $2.7 billion acquisition of ZS Pharma.
AstraZeneca potassium drug finally approved, threatening Vifor LONDON (Reuters) – The decision by U.S. regulators to finally approve AstraZeneca’s much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.
AstraZeneca can finally try to reap some returns from its $2.7 billion buyout of ZS Pharma. After back-to-back rejections over manufacturing problems, its potential blockbuster hyperkalemia drug Lokelma, formerly known as ZS-9, has finally been approved by the FDA.
AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Forxiga (dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).
Zoetis Position in Veterinary Diagnostics Space Will Strengthen Following Abaxis Acquisition
Shares of Bayer AG (BAYN), a German pharmaceutical and life sciences company, are down just 0.10% on Friday after a positive week in which the stock gained 2% in the period of May 14 to May 18.
THOUSAND OAKS, Calif.,May 21, 2018/PRNewswire/ --Amgen(NASDAQ:AMGN) today announced that theU.S. Food and Drug Administration(FDA) has approved the use of Prolia®(denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.